211 related articles for article (PubMed ID: 23948883)
1. Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele.
Qiu WQ; Mwamburi M; Besser LM; Zhu H; Li H; Wallack M; Phillips L; Qiao L; Budson AE; Stern R; Kowall N
J Alzheimers Dis; 2013; 37(2):421-8. PubMed ID: 23948883
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele.
Qiu WW; Lai A; Mon T; Mwamburi M; Taylor W; Rosenzweig J; Kowall N; Stern R; Zhu H; Steffens DC
Am J Geriatr Psychiatry; 2014 Feb; 22(2):177-85. PubMed ID: 23567418
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
de Oliveira FF; Chen ES; Smith MC; Bertolucci PHF
Curr Alzheimer Res; 2018 Feb; 15(4):386-398. PubMed ID: 29034839
[TBL] [Abstract][Full Text] [Related]
4. The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status.
Ouk M; Wu CY; Rabin JS; Jackson A; Edwards JD; Ramirez J; Masellis M; Swartz RH; Herrmann N; Lanctôt KL; Black SE; Swardfager W
Alzheimers Res Ther; 2021 Feb; 13(1):43. PubMed ID: 33573702
[TBL] [Abstract][Full Text] [Related]
5. In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.
Tangwongchai S; Supasitthumrong T; Hemrunroj S; Tunvirachaisakul C; Chuchuen P; Houngngam N; Snabboon T; Tawankanjanachot I; Likitchareon Y; Phanthumchindad K; Maes M
Mol Neurobiol; 2018 Aug; 55(8):6449-6462. PubMed ID: 29307083
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of angiotensin modulators according to
Oliveira FF; Almeida SS; Chen ES; Smith MC; Bertolucci PHF
Acta Neuropsychiatr; 2023 Dec; 35(6):346-361. PubMed ID: 37605989
[TBL] [Abstract][Full Text] [Related]
7. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.
Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD;
JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease.
Qiu WQ; Zhu H; Dean M; Liu Z; Vu L; Fan G; Li H; Mwamburi M; Steffens DC; Au R
Int J Geriatr Psychiatry; 2016 Mar; 31(3):316-22. PubMed ID: 26250797
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
[TBL] [Abstract][Full Text] [Related]
10. The insertion polymorphism in angiotensin-converting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease.
Wang B; Jin F; Yang Z; Lu Z; Kan R; Li S; Zheng C; Wang L
J Mol Neurosci; 2006; 30(3):267-71. PubMed ID: 17401152
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin converting enzyme insertion/deletion polymorphism in sporadic and familial Alzheimer's disease and longevity.
Nacmias B; Bagnoli S; Tedde A; Cellini E; Bessi V; Guarnieri B; Ortensi L; Piacentini S; Bracco L; Sorbi S
Arch Gerontol Geriatr; 2007; 45(2):201-6. PubMed ID: 17182125
[TBL] [Abstract][Full Text] [Related]
12. Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease.
Morris JK; Uy RAZ; Vidoni ED; Wilkins HM; Archer AE; Thyfault JP; Miles JM; Burns JM
J Alzheimers Dis; 2017; 58(4):1129-1135. PubMed ID: 28550261
[TBL] [Abstract][Full Text] [Related]
13. Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers.
Tao Q; Ang TFA; DeCarli C; Auerbach SH; Devine S; Stein TD; Zhang X; Massaro J; Au R; Qiu WQ
JAMA Netw Open; 2018 Oct; 1(6):e183597. PubMed ID: 30646251
[TBL] [Abstract][Full Text] [Related]
14. Association between ACE polymorphism, cognitive phenotype and APOE E4 allele in a Tunisian population with Alzheimer disease.
Achouri-Rassas A; Ali NB; Cherif A; Fray S; Siala H; Zakraoui NO; Hadj-Fredj S; Kechaou M; Anane N; Echebi S; Messaoud T; Belal S
J Neural Transm (Vienna); 2016 Mar; 123(3):317-21. PubMed ID: 26456241
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and overweight associate with non-APOE4 genotype in an Alzheimer's disease population.
Profenno LA; Faraone SV
Am J Med Genet B Neuropsychiatr Genet; 2008 Sep; 147B(6):822-9. PubMed ID: 18189240
[TBL] [Abstract][Full Text] [Related]
16. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
[TBL] [Abstract][Full Text] [Related]
17. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.
Leduc V; De Beaumont L; Théroux L; Dea D; Aisen P; Petersen RC; ; Dufour R; Poirier J
Mol Psychiatry; 2015 Jul; 20(7):867-73. PubMed ID: 25023145
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.
Poirier J; Delisle MC; Quirion R; Aubert I; Farlow M; Lahiri D; Hui S; Bertrand P; Nalbantoglu J; Gilfix BM; Gauthier S
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12260-4. PubMed ID: 8618881
[TBL] [Abstract][Full Text] [Related]
19. APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis.
Fukumoto H; Ingelsson M; Gårevik N; Wahlund LO; Nukina N; Yaguchi Y; Shibata M; Hyman BT; Rebeck GW; Irizarry MC
Exp Neurol; 2003 Sep; 183(1):249-53. PubMed ID: 12957508
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-β and tau pathology.
Kehoe PG; Wong S; Al Mulhim N; Palmer LE; Miners JS
Alzheimers Res Ther; 2016 Nov; 8(1):50. PubMed ID: 27884212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
